Project kickoff

Other Transaction IDV Awarded Last action

Contract number
W911SR2290003
Awardee
Awarding agency
Task orders
0

Award facts

Last date to order
Not on record
IDV ceiling
$22,346,183.48
Contracting staff
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
NAICS code
Not on record
Set-aside
No set-aside
Competition
Competed Broad Agency Announcement
Pricing
Other

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

The Department of the Army's Joint Program Executive Office Chemical and Biological Defense awarded an Other Transaction IDV to Partner Therapeutics, Inc. on January 7, 2022, with a ceiling value of $22,346,183.48. The OT IDV sits outside the FAR and is designed to support FDA approval for Leukine (sargramostim) to treat myelosuppressive effects and restore hematopoietic and immune function following sulfur mustard gas exposure.

Partner Therapeutics, a biopharmaceutical manufacturer based in Lexington, Massachusetts, specializes in therapeutics for neutropenia, sepsis, and other urgent medical conditions, with particular depth in sargramostim supply and immunological biomarker development. The company holds FDA approval and manufacturing capability for Leukine and has established relationships with the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response as a primary medical countermeasure supplier across multiple delivery and task order vehicles.

The OT IDV represents the Joint PEO Chemical and Biological Defense's investment in advancing the regulatory pathway for Leukine as a medical countermeasure for chemical defense applications, leveraging Partner Therapeutics' existing manufacturing expertise and FDA-approved product portfolio to accelerate approval under this alternative acquisition authority.

Transactions

Action Obligated Date
Funding Only Action P00017 $1,542,499
Funding Only Action P00016 $37,315
Supplemental Agreement for work within scope P00015 $994,523
Supplemental Agreement for work within scope P00014 $2,346,472
Supplemental Agreement for work within scope P00013 $4,325,313
Funding Only Action P00012 $1,301,657
Supplemental Agreement for work within scope P00011 $1,512,692
Funding Only Action P00010 -$352,108
Funding Only Action P00009 · The purpose of this agreement is to apply for food and drug administration approval for the use of leukine to treat the myelosuppressive effects and restore… $350,048
Funding Only Action P00008 · Incremental funding for PK study, leukine HD agreement $168,527
Supplemental Agreement for work within scope P00007 · Add funding reduce value of clins 0045-0047 $518,691
Supplemental Agreement for work within scope P00006 · Increase value by adding optional clins for potential pharmacokinetic (PK) studies required by FDA. $2,841,733
Supplemental Agreement for work within scope P00005 · Partner therapeutics developing medical countermeasure for mustard gas. -$2,269,030
Funding Only Action P00004 · Incremental funding modification to ongoing OTA prototype agreement for r & d FDA approved mustard gas treatment. $1,229,592
Supplemental Agreement for work within scope P00003 · Prototype project to determine efficacy of leukine against mustard gas exposure. $830,539
Supplemental Agreement for work within scope P00002 · Additional within scope work with a value of $2,791,598.00 for continued research and development of a sulfur mustard gas prototype treatment. $1,139,434
Other Administrative Action P00001 · Update government administrative points of contact and provide incremental funding for prototype project for delivery of an FDA approved treatment after… $1,659,019
Original award $3,159,014
Show all 18

Quick answers

Who was awarded contract W911SR2290003?

W911SR2290003 was awarded to Partner Therapeutics, Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on January 7, 2022.

How much is contract W911SR2290003 worth?

W911SR2290003's own ceiling is $22,346,183.

Which agency awarded contract W911SR2290003?

ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911SR2290003, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

Was contract W911SR2290003 competed?

The extent of competition for W911SR2290003 was competed.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login